Fig. 2: Efficacy outcomes.

a, Proportion of patients who achieved WI-NRS improvement (reduction) by ≥4 points from baseline at week 12 and week 24. b, Proportion of patients who achieved IGA PN-S score of 0 or 1 (‘clear’ or ‘almost clear’) at week 12 and week 24. c, Proportion of patients who achieved concomitantly WI-NRS reduction from baseline by ≥4 points and IGA PN-S of score 0 or 1 at week 24 in PRIME and PRIME2. *Endpoint not in the testing hierarchy. Cochran–Mantel–Haenszel test was performed on the association between the responder status and intervention group, adjusted by documented history of atopy (atopic or non-atopic), stable use of TCS/TCI (yes or no), region and baseline antidepressant use (yes or no).